Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in...( ANN ARBOR Mich. Sept. 6 /- Terumo...),Health

ANN ARBOR, Mich., Sept. 6 /PRNewswire/ -- Terumo Heart Inc. announced today that it is planning a European Launch Symposium at the European Association of Cardio-Thoracic Surgeons (EACTS) meeting in Geneva, Switzerland on September 17, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061027/DEF004LOGO

http://www.newscom.com/cgi-bin/prnh/20070227/CLTU043LOGO )

A summary of the European Clinical Trial results for the company's DuraHeart(TM) Left Ventricular Assist System (LVAS) will be presented by Dr. Aly El-Banayosy from the Heart Center Nordrhine-Westaflen, Bad Oeynhausen, Germany. This will be followed by a presentation from Dr. Eric Rose, Professor of Surgery at Columbia University Medical Center in New York, entitled "The Emerging New Era of Mechanical Circulatory Support".

The EACTS meeting will mark the official launch of the DuraHeart LVAS. The device has been on the market in Europe for several months and is experiencing significant interest since achieving a CE Mark earlier in the year.

The DuraHeart LVAS is a 3rd generation circulatory support device with full magnetic levitation, intended to provide cardiac support for patients who are at risk of death due to end-stage left ventricular failure. It is the only approved implantable Left Ventricular Assist System combining a centrifugal pump with magnetic levitation of the impeller, providing exceptional reliability and minimizing the potential for blood damage and thrombus. The DuraHeart System is not available in the United States.

Terumo Heart Inc. is a U.S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the innovation and introduction of products to improve the quality of healthcare for the heart failure pat
'/>"/>